A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Contemporary Patients With Metastatic Castration-Resistant Prostate Cancer in the PRECISION Data Platform
About This Trial
- This study reviews existing medical records to learn how advanced prostate cancer that has spread and no longer responds to hormone therapy is treated in everyday medical care.
- It is for adult men who were diagnosed with this specific stage of prostate cancer between 2021 and 2025.
- Researchers want to see which therapies are used most often and how well patients do on them over time.
- Before considering this study, you should know that it does not test any new drugs or require extra appointments, so taking part will not change your normal cancer care.
More Information
- The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice.
- This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Who Can Enroll
- Age Range: 18 - 115 years
- Gender: Male
- Who This Trial is For: This study reviews existing medical records to learn how advanced prostate cancer that has spread and no longer responds to hormone therapy is treated in everyday medical care.
Study Details
- Start Date: June 30, 2026
- Lead Sponsor: Novartis Pharmaceuticals
Full Eligibility Criteria
Inclusion Criteria
- Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.
- Male sex at index, where index is the date of initial mCRPC diagnosis.
- Age 18 years at index.
Exclusion Criteria
• None